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The gene GAD2 encoding the glutamic acid decarboxylase enzyme (GAD65) is a positional candidate gene for obesity
on Chromosome 10p11–12, a susceptibility locus for morbid obesity in four independent ethnic populations. GAD65
catalyzes the formation of c-aminobutyric acid (GABA), which interacts with neuropeptide Y in the paraventricular
nucleus to contribute to stimulate food intake. A case-control study (575 morbidly obese and 646 control subjects)
analyzing GAD2 variants identified both a protective haplotype, including the most frequent alleles of single
nucleotide polymorphisms (SNPs)þ61450 C.A andþ83897 T.A (OR¼0.81, 95% CI [0.681–0.972], p¼0.0049) and an
at-risk SNP ( 243 A.G) for morbid obesity (OR ¼ 1.3, 95% CI [1.053–1.585], p ¼ 0.014). Furthermore, familial-based
analyses confirmed the association with the obesity of SNP þ61450 C.A and þ83897 T.A haplotype (v
2 ¼ 7.637, p ¼
0.02). In the murine insulinoma cell line bTC3, the G at-risk allele of SNP 243 A.G increased six times GAD2 promoter
activity (p , 0.0001) and induced a 6-fold higher affinity for nuclear extracts. The 243 A.G SNP was associated with
higher hunger scores (p¼0.007) and disinhibition scores (p¼0.028), as assessed by the Stunkard Three-Factor Eating
Questionnaire. As GAD2 is highly expressed in pancreatic b cells, we analyzed GAD65 antibody level as a marker of b-
cell activity and of insulin secretion. In the control group,  243 A.G, þ61450 C.A, and þ83897 T.A SNPs were
associated with lower GAD65 autoantibody levels (p values of 0.003, 0.047, and 0.006, respectively). SNPþ83897 T.A
was associated with lower fasting insulin and insulin secretion, as assessed by the HOMA-B% homeostasis model of b-
cell function (p¼ 0.009 and 0.01, respectively). These data support the hypothesis of the orexigenic effect of GABA in
humans and of a contribution of genes involved in GABA metabolism in the modulation of food intake and in the
development of morbid obesity.
Introduction
The strong evidence for a genetic component to human
obesity has been unequivocally established over the past years
with the identiﬁcation of the genetic defects responsible for
different monogenic forms, being involved in 4% of cases of
human obesity (Clement et al. 2002). However, the role of
genetic factors in common obesity is complex, being
determined by the interaction of several genes (polygenic),
each of which may have relatively small effects (i.e., they are
susceptibility genes) and which may work in combination
with each other as well as with environmental factors (e.g.,
nutrient intake and physical activity). The examination of
candidate genes for involvement in the susceptibility to
common obesity has not yet yielded convincing results
(Chagnon et al. 2003). Another approach used for identifying
genes underlying common polygenic obesity utilizes genome-
wide scans in order to detect chromosomal regions showing
linkage with obesity in large collections of nuclear families.
The power of this approach was proven in other complex
traits (Horikawa et al. 2000; Gretarsdottir et al. 2003). A
genome-wide scan performed in 158 multiplex French obese
Caucasian families (514 individuals) having at least one
subject with a body mass index (BMI) of greater than 40 kg/
m
2 and at least one further sibling with a BMI of greater than
27 kg/m
2 reported signiﬁcant evidence for linkage of obesity
to a Chromosome 10p locus (Hager et al. 1998), with a
maximal logarithm of odds (LOD) score (MLS) near the
D10S197 marker. Replication studies in both European-
American and African-American cohorts conﬁrmed the
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PLoS BIOLOGYmaximum nonparametric linkage peak at D10S197 for the
combined sample set (Price et al. 2001) as well as for a
German young obese sib cohort (Saar et al. 2003). All
together, these independent linkage studies strengthen the
hypothesis of a susceptibility gene for obesity in the
Chromosome 10p11–12 locus. Marker D10S197 is located in
intron 7 of the GAD2 gene encoding the glutamic acid
decarboxylase enzyme (GAD65). GAD65 catalyzes the for-
mation of c-aminobutyric acid (GABA) from L-glutamic acid
and is expressed in both pancreatic islets and brain (Erdo and
Wolff 1990). GABA is colocalized in neuropeptide Y (NPY)
neurons and is involved in the leptin pathway through the
arcuate nucleus in the hypothalamus (Ovesjo et al. 2001).
GABA interacts with NPY in the paraventricular nucleus to
stimulate food intake (Pu et al. 1999). The bilateral injection
of GAD2 antisense oligodeoxynucleotide into rat ventrome-
dial hypothalamus decreased the content of GABA by 50% 24
h after the injection, decreasing food intake, while also
enhancing locomotor activity (Bannai et al. 1998).
We here report genetic and functional arguments in favor
of the GAD2 gene as a positional candidate gene for obesity
on the Chromosome 10p locus.
Results
Fine Mapping of the Chromosome 10p Locus
In order to cover the Chromosome 10p linkage region with
obesity at a density of one marker every centimorgan, 16
polymorphic markers between D10S191 and D10S220 were
further genotyped in 188 nuclear families comprising 620
individuals. Single-point analyses showed a cluster of markers
with an MLS higher than 1. D10S1639, D10S197, and D10S600
markers displayed an MLS of 3.4, 3.3, and 2.54, respectively
(Figure 1A). Multipoint analysis revealed two peaks, at the
D10S197 (MLS ¼ 3.2) and D10S600 (MLS ¼ 3.4) markers,
respectively. As D10S197 is located in intron 7 of the GAD2
gene, we sought association of alleles or group of alleles of
this marker with obesity. Allele frequencies were compared
between obese and control subjects. Empirical p value for the
normal statistics was 0.0017 and for the lumped allele (Lall)
statistics was 0.01, respectively (data not shown), suggesting
that a functional single nucleotide polymorphism (SNP) in
partial linkage disequilibrium (LD) with the D10S197 marker
may be located nearby.
GAD2 Gene: SNP Map and Association Studies with
Obesity
GAD2 coding sequences (introns and exons) 3 kb upstream
from the 59 untranslated region (UTR) and 3 kb downstream
from the 39 UTR were screened for mutations in 24 obese
patients from families showing evidence of linkage at the
Chromosome 10p locus and in 24 nonobese subjects. In
addition, we genotyped previously reported SNPs (Johnson et
al. 2002) and those from public databases. On the basis of
their frequency and location in a coding or a putative
regulating region, 15 SNPs (Figure 1B; Table 1) were then
selected for association studies. As families from the genome-
wide scan were recruited through a proband with a BMI
greater than 40 kg/m
2, we postulated that the Chromosome
10p putative susceptibility gene may be primarily associated
with morbid obesity, which represents less than 1% of the
adult population in France (Charles et al. 2002). Thus, 15
SNPs were genotyped in 48 unrelated morbidly obese
patients from families showing evidence of linkage at the
Chromosome 10p locus and in 48 nonobese control subjects.
For further extensive case-control study, six SNPs  2625
A.G,  243 A.G( 5 9 ﬂanking region), þ84 G.A (intron 1),
þ61450 C.A (intron 11), þ70210 A.T (intron 13), and
þ83897 T.A (intron 15) were selected, as they were not in
complete LD between each other (2) and their frequency
was higher than 10% and thus could account for the genetic
variability of the GAD2 gene.
The six SNPs were genotyped in 349 unrelated morbidly
obese patients, in 383 unrelated moderately obese subjects,
and in 376 unrelated nonobese normoglycemic subjects. We
observed a ﬁrst indication for association (or trend) between
morbid obesity and four SNPs at position  243 A.G, þ84
G.A, 61450 C.A, and þ83897 T.A (0.035 , p , 0.1; 1.27 .
odds ratio [OR] . 1.02). No association was observed between
any SNP and moderate obesity (0.2 , p , 0.93) (data not
shown). As we cannot exclude an effect of uncommon
polymorphisms (prevalence, ,5%) in the coding regions on
morbid obesity, we genotyped SNPsþ2414 C.A (Pro153Gln),
þ53881 C.T (Thr339Thr), and þ70210 A.T in this ﬁrst
cohort. No association between these SNPs and obesity was
observed (data not shown).
In order to conﬁrm these results, we genotyped 243 A.G,
þ84 G.A,þ61450 C.A, andþ83897 T.A SNPs in additional
sets of 226 unrelated morbidly obese subjects with familial
history of obesity and of 270 nonobese normoglycemic
subjects selected from 294 families representative of the
general population from northern France. In this replication
study, a trend for association between the G allele of the 243
A.G SNP and morbid obesity was found (OR ¼ 1.25 [0.906–
1.722], p ¼ 0.17). Analysis of pooled data of both studies
conﬁrmed the association between the  243 A.G SNP and
morbid obesity (OR ¼ 1.3, 95% conﬁdence interval [CI]
[1.053–1.585], p ¼ 0.014; Table 2). A trend toward association
was observed for SNPþ61450 C.A (OR¼1.2, 95% CI [0.997–
1.423], p ¼ 0.06). No association was detected for SNPs þ84
G.A and þ83897 T.A. The risk alleles were the G and A
alleles for SNP 243 A.G and SNPþ61450 C.A, respectively.
Haplotype analyses of SNPs  243 A.G, þ84 G.A, þ61450
C.A, and þ83897 T.A were then performed by both
haplotype trend regression (HTR) and permutation and
model-free analysis and estimation haplotype (PMþEHþ)
methods. Haplotypes including SNP þ84 G.A with each of
the three remaining SNPs did not improve association with
morbid obesity, and indeed association of SNP þ84 G.A
resulted from its LD with the other three SNPs (data not
shown). Thus, SNP þ84 G.A was excluded from further
haplotype analyses. Haplotype structures, including the three
SNPs  243 A.G, þ61450 C.A, and þ83897 T.A, were then
investigated in the 575 unrelated morbidly obese patients
with familial history of obesity and in the 646 nonobese
subjects. Among the eight possible haplotypes deﬁned by
SNPs 243,þ61450, andþ83897, only six haplotypes displayed
a frequency of greater than 1% and their combined
prevalence encompassed all but 2% of the haplotypes seen
in the population (Table 3).
Comparison of haplotype frequencies performed by HTR
between cases and controls showed evidence for association
with obesity with an empirical p value of 0.0004. This positive
result was ascertained by a PMþEHþ analysis (p ¼ 0.0002).
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GAD2 Gene and Morbid ObesityFrequencies of haplotypes bearing the wild-type alleles (A–C–
T) were signiﬁcantly higher in nonobese compared to the
morbidly obese group (Table 3). It is noteworthy that the risk
G allele at SNP  243 A.G was present on several haplotypes
with frequencies lower than 1% that cannot be taken into
account for the haplotype analysis. SNPs  243, þ61450, and
þ83897 were in strong LD, and the v
2 between these markers
ranged from 556 to 1265; thus, p values were ,0.00001. In
addition, posterior probabilities of haplotype accuracy, as
assayed by software for estimating frequencies of large
haplotypes of SNPs, SNPHAP, were greater than 0.98 for
98% of the subjects included in the study. For the remaining
Figure 1. Mapping of Chromosome 10p
and the GAD2 Gene
(A) Fine mapping of the Chromosome
10p locus between markers D10S548 and
D10S220 in 188 nuclear families (620
individuals). Multipoint analysis for obe-
sity phenotype.
(B) SNP map of the GAD2 gene. Positions
were assigned according the location to
the A of the ATG. The 15 SNPs selected
for association studies are indicated in
red. See also Table 1.
DOI: 10.1371/journal.pbio.0000068.g001
Table 1. Allele Frequency and Hardy–Weinberg Equilibrium Statistics for 15 SNPs Selected for Association Studies
SNPs Allele Frequency
in 48 Unrelated
Morbidly Obeses
Allele Frequency
in 48
Nonobese Controls
p Value
of Allele Frequency
p Value
of Hardy–Weinberg
Equilibrium Statistics
 2625 A.G G: 0.11 G: 0.12 0.88 0.44
 2004 A.T T: 0.20 T: 0.12 0.18 0.62
 1600 G.A A: 0.16 A: 0.10 0.22 0.57
 243 A.G G: 0.18 G: 0.12 0.25 1
þ84 G.A A: 0.18 A: 0.16 0.104 0.35
þ2414 C.A A: 0.01 A: 0.005 1 1
þ7578 T.C C: 0.15 C: 0.12 0.55 0.07
þ29208 C.T T: 0.21 T: 0.14 0.21 0.65
þ53842 G.C C: 0.16 C: 0.14 0.58 0.07
þ53881 C.T T: 0.023 T: 0.023 1 1
þ61450 C.A A: 0.43 A: 0.27 0.026 1
þ70166 delT DelT: 0.17 DelT: 0.15 0.69 0.1
þ70210 A.T T: 0.013 T: 0.069 0.11 1
þ83897 T.A A: 0.21 A: 0.13 0.11 0.65
þ84585 A.T T: 0.16 T: 0.15 0.85 0.17
DOI: 10.1371/journal.pbio.0000068.t001
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0.98. Moreover, on a background wild-type CC for SNP
þ61450 C.A or TT for SNPþ83897 T.A, association of SNP
 243 A.G with morbid obesity remained signiﬁcant (p¼0.01
and p ¼ 0.03, respectively). The independent effect of  243
A.G was conﬁrmed by haplotype analysis of SNPs þ61450
C.A and þ83897 T.A that presented a signiﬁcant associa-
tion with morbid obesity, overall permutation showing an
empirical p , 0.0001. Estimated frequencies of haplotype
bearing the wild-type alleles (C–T) remained higher in the
nonobese compared to the morbidly obese group (p¼0.0049).
Thus, the C–T haplotype displayed a ‘‘protective’’ effect
against obesity (OR ¼ 0.81, 95% CI [0.681–0.972]).
Linkage, Familial Association, and Association with the
Evidence of Linkage of GAD SNPs
Familial association and association with the evidence of
linkage were investigated in the 188 nuclear families (612
individuals). First, as expected in a region of linkage, the SNPs
 243 A.G,þ61450 C.A, andþ83897 T.A showed signiﬁcant
linkage with a binary obese status, displaying an MLS of,
respectively, 2.54, 1.86, and 4.54 (data not shown). The SNPs
of GAD certainly show linkage with obesity and that they are,
therefore, worth investigating for familial-based association
tests (FBATs).
The FBAT was used to detect association in our established
linkage context. In single SNP analyses, we observed an
association and an excess of wild-type alleles in nonaffected
offspring for SNPs þ61450 C.A and þ83897 T.A( Z ¼ 2.17,
p ¼ 0.03 and Z ¼  2.09, p ¼ 0.03, respectively) and a trend
toward association and excess of G allele for SNP  243 A.G
in affected offspring (Z ¼ 1.87, p ¼ 0.06). For haplotype
analysis of SNPs þ61450 C.A and þ83897 T.A, the global
test for association with obesity was signiﬁcant (v
2¼7.637, p¼
0.02). The protective wild-type (C–T) haplotype was in excess
in nonaffected offspring (Z ¼  1.94, p ¼ 0.05) (Table 3).
Table 2. Comparison of Genotypic and Allelic Distribution of the 243 A.G,þ84 G.A,þ61450 C.A, andþ83897 T.A SNPs between
the Morbidly Obese and Nonobese Groups
Cohorts Status Genotypes n (Frequency) p Value OR
 243 A.G AA AG GG Allele Frequency 95%CI
First set Morbidly obese 217 (0.62) 116 (0.34) 15 (0.04) 0.04 1.32 [1.014–1.725]
Nonobese 262 (0.71) 94 (0.25) 15 (0.04)
Second set Morbidly obese 138 (0.62) 74 (0.33) 12 (0.05) 0.17 1.25 [0.906–1.722]
Nonobese 159 (0.66) 79 (0.32) 5 (0.02)
Pooled set Morbidly obese 355 (0.62) 190 (0.33) 27 (0.05) 0.014 1.3 [1.053–1.585]
Nonobese 421 (0.68) 173 (0.28) 20 (0.04)
þ84 G.AG G G A A A
First set Morbidly obese 221 (0.66) 105 (0.31) 11 (0.03) 0.14 1.23 [0.935–1.626]
Nonobese 263 (0.72) 90 (0.25) 13 (0.03)
Second set Morbidly obese 149 (0.66) 67 (0.30) 8 (0.04) 0.78 1.04 [0.757–1.443]
Nonobese 169 (0.64) 87 (0.33) 7 (0.03)
Pooled set Morbidly obese 374 (0.66) 175 (0.31) 19 (0.03) 0.34 1.1 [0.898–1.364]
Nonobese 432 (0.69) 177 (0.28) 20 (0.03)
þ61450 C.AC C C A A A
First set Morbidly obese 159 (0.47) 140 (0.41) 39 (0.12) 0.04 1.28 [1.019–1.622]
Nonobese 190 (0.55) 125 (0.36) 31 (0.09)
Second set Morbidly obese 93 (0.46) 84 (0.42) 23 (0.12) 0.57 1.1 [0.820–1.433]
Nonobese 126 (0.48) 115 (0.43) 24 (0.09)
Pooled set Morbidly obese 252 (0.47) 224 (0.42) 62 (0.11) 0.06 1.2 [0.997–1.423]
Nonobese 316 (0.52) 240 (0.39) 55 (0.09)
þ83897 T.AT T T A A A
First set Morbidly obese 200 (0.64) 101 (0.32) 14 (0.04) 0.036 1.34 [1.019–1.777]
Nonobese 254 (0.71) 93 (0.26) 11 (0.03)
Second set Morbidly obese 149 (0.66) 69 (0.31) 7 (0.03) 0.76 0.97 [0.759–1.451]
Nonobese 166 (0.64) 85 (0.33) 7 (0.03)
Pooled set Morbidly obese 368 (0.65) 179 (0.31) 22 (0.04) 0.16 1.16 [0.942–1.427]
Nonobese 420 (0.68) 178 (0.29) 18 (0.03)
First set: 349 morbidly obese patients and 376 nonobese and normoglycemic subjects. Second set: 226 morbidly obese subjects and 270 nonobese and normoglycemic
subjects. Number of individual per genotype and status (frequencies are between brackets).
DOI: 10.1371/journal.pbio.0000068.t002
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observed for SNP þ61450 C.A. Seventeen nuclear families,
with concordant affected sibpairs for the A–A genotype,
displayed a LOD score of 4.13, p¼0.02 (as this LOD score was
reached 20 times out of 1,000 simulations, assessing a C allele
frequency of 0.72, the value in the control cohorts). When
considering a C allele frequency of 0.68 (value in the morbidly
obese cohorts), a p value of 0.06 was observed. Remaining
sibpairs nonconcordant for this genotype displayed a LOD
score of 1.75. Thus, it is impossible to exclude that SNP
þ61450 C.A explains the observed linkage.
LD Analysis of the GAD2 Region
To conﬁrm that the GAD2 gene itself is responsible for the
observed LD with obesity around the D10S197 marker,
pairwise LD among SNPs in the region was investigated and
graphically represented using the GOLD software (http://
www.well.ox.ac.uk/asthma/gold). Various studies reported that
LD extends between 10 and 30 kb for common alleles (Ardlie
et al. 2002a), whereas others showed that it may extend to 60
kb (Reich et al. 2001). Then, LD analysis was performed in a
300 kb region including the GAD2 gene and its only known
nearby gene MYO3A, located 4.14 kb downstream the GAD2
gene. MYO3A belongs to the myosin superfamily, and its
mutations are responsible for a nonsyndromic progressive
hearing loss (Walsh et al. 2002). LD analysis of 28 SNPs
covering the 300 kb region including GAD2 and MYO3A genes
showed that they belong to distinct blocks of LD (Figure 2).
SNPs in the MYO3A gene were not in LD with those of the
GAD2 gene. Moreover, none of the MYO3A SNPs was
associated with obesity or related phenotypes (data not
shown), suggesting that the observed association with morbid
obesity is likely to be due to the GAD2 gene itself.
The G Allele at the SNP  243 A.G Variant Increases the
GAD2 Gene Transcription Level
The  243 A.G SNP displayed the highest level of
association with massive obesity and is located in the 59
ﬂanking region. We therefore sought to know whether it was
involved in the expression of the GAD2 gene. As the  243
A.G was in strong LD with two promoter SNPs, 1600 G.A
(D9 ¼ 0.991), and  2004 A.T( D 9 ¼ 0.996) SNPs, we
investigated the potential effect of the three individual SNPs
on GAD2 transcription. The luciferase reporter gene was used
to measure promoter activity. bTC3 cells (murine insulinoma
cell line) were transiently cotransfected with the promoter
constructs and control vectors. The transcriptional activity of
the  2 4 3G / Gm u t a n tc o n s t r u c tw a ss i xt i m e sh i g h e r
compared to the wild-type  243 A/A construct (n ¼ 8, p ,
0.0001) (Figure 3). In contrast, the  1600 A/A and  2004 T/T
constructs showed, respectively, a similar pattern of tran-
scriptional activity and a decrease of 25% of transcriptional
activity compared to wild-type construct.
To examine the effects of the  243 .G SNP on binding
afﬁnity and speciﬁcity for transcription, electrophoretic
mobility shift assays (EMSAs) were performed using nuclear
Table 3. Haplotype Analysis of the Obese Status in 575 Morbidly Obese and 646 Control Subjects
Haplotypes Case-Control Test FBAT
 243 A.G þ61450 C.A þ83897 T.A Nonobese Morbidly Obese p Value Znorm p Value
1(A) 1(C) 1(T) 70.6 64.3 0.003  1.92 0.05
2(G) 2(A) 2(A) 15 16 0.40 1.56 0.12
1(A) 2(A) 1(T) 11 12.8 0.023 1.15 0.25
2(G) 2(A) 1(T) 0.9 2.24 0.025
2(G) 1(C) 2(A) 0.09 1.3 0.003
1(G) 1(C) 2(A) 0.2 1 0.87
1(C) 1(T) 71.2 65.3 0.0049  1.94 0.05
2(A) 2(A) 16.6 17.1 0.59 1.73 0.08
2(A) 1(T) 11.8 15.11 0.044 1.14 0.25
1(C) 2(A) 0.4 2.4 0.0003
Haplotypes covering three ( 243 ,þ61450,þ83897) and two (þ61450,þ83897) SNPs have been investigated. FBAT was performed for each haplotype. A positive Znorm means
that there is an excess of allele in affected offspring. 1 ¼ wild-type allele; 2 ¼ variant allele. The corresponding nucleotides are shown as subscripts in parentheses.
DOI: 10.1371/journal.pbio.0000068.t003
Figure 2. Pairwise LD between SNPs of GAD2 and MYO3 Genes in the
French Obese Population
Pairwise LD between SNPs is measured by triangles (color scale).
Regions of high and low LD are represented by red and blue shading,
respectively. The graph is not to scale; indeed, the SNPs are
equidistant to highlight the detailed pattern of LD.
DOI: 10.1371/journal.pbio.0000068.g002
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GAD2 Gene and Morbid Obesityextracts from bTC3 cells and two pairs of DNA oligonucleo-
tide probes that differed only by the SNP. A shift was
observed with the probe containing the  243 A allele,
showing that this DNA sequence is able to bind a nuclear
protein (Figure 4). Furthermore, comparisons of binding
capacity of the probes containing  243 A and  243 G,
respectively, showed that bTC3 nuclear proteins have a 6-fold
higher afﬁnity for the G allele variant than for the A allele of
 243 A.G (Figure 4). Computational analysis of the 243 G/A
ﬂanking sequences did not show a putative binding site for
tissue-speciﬁc (brain, b cells, pancreas) transfactors.
Association Study between SNP 243 A.G and Scores on
the Three Factor Eating Questionnaire (Restraint, Disinhi-
bition, and Hunger)
To further explore the contribution of the GAD2 gene and
especially of its functional polymorphism, 243 A.G SNP, in
the modulation of food intake, we analyzed data obtained
through the Three-Factor Eating Questionnaire (TFEQ)
(Stunkard and Messick 1985) in the morbidly obese popula-
tion. This questionnaire was proposed to evaluate dietary
restraint (factor 1), disinhibition (factor 2), and hunger
(factor 3) indexes. In morbidly obese subjects, SNP  243
A.G was associated with scores of the TFEQ. The homo-
zygote variant GG for SNP 243 A.G showed higher hunger
and disinhibition scores (p¼0.007 and p¼0.028, respectively)
(Figure 5). SNPs þ61450 C.A and þ83897 T.A were also
evaluated for these scores, but only SNPþ83897 T.A showed
signiﬁcant association with the hunger score (p ¼ 0.04).
Association with eating parameters and haplotype including
SNPs þ61450 C.Aa n dþ83897 T.Ad i dn o tr e a c h
signiﬁcance.
Haplotype including the wild-type alleles (A–C–T) for SNPs
 243 A.G, þ61450 C.A, and þ83897 T.A was associated
with a lower hunger score than haplotype including variant
alleles (G–A–A) (p ¼ 0.01 by HTR). A similar nonsigniﬁcant
trend was observed for the disinhibition score (p ¼ 0.08 by
HTR). The TFEQ was not available in nonobese subjects.
Association Study with GAD65 Autoantibodies
A correlation between GAD65 autoantibody (GAD65Ab)
levels and high BMI previously reported in a Swedish
population was assumed to be related with the obesity-
associated hyperinsulinemia that stimulates the generation of
GAD65Ab (Rolandsson et al. 1999). In order to conﬁrm that
GAD2 SNPs may indirectly modulate insulin secretion, thus
interacting with food intake regulation, we investigated their
potential effect on GAD65Ab level. As the distribution of
GAD65Ab indexes was not normally distributed, we consid-
Figure 3. Effect of the 243 A.G, 1600 G.A, and 2004 A.T SNPs on
Transcriptional Activity
G, A, and T alleles at  243 A.G,  1600 G.A, and  2004 A.T SNPs
were generated into the wild-type construct (wt). bTC3 cells were
transfected with equivalent amounts of pGL3, wild-type, Gad-2004T,
Gad-1600A, and Gad-243G constructs. pRLTK was cotransfected with
each construct. Luciferase and Renilla activities were assayed and
normalized. Each experiment was performed in duplicate and
replicated ﬁve times. A 6-fold increase of transcriptional activity
was observed for the Gad-243 as compared to the wild-type construct.
DOI: 10.1371/journal.pbio.0000068.g003
Figure 4. EMSA of the the  243 A.G Polymorphism with bTC3 Nuclear
Proteins
Speciﬁc complex formation is indicated by an arrow. Lanes ( ) are
radiolabeled probes without nuclear extract. bTC3 nuclear proteins
have an higher afﬁnity for the G allele variant than for the A allele at
SNP  243 A.G.
DOI: 10.1371/journal.pbio.0000068.g004
Figure 5. Association Studies of the 243 A.G Variant with Food Intake
Behavior Parameters in Morbidly Obese Patients
The three stable factors—cognitive restraint of eating, disinibition,
and hunger—were assessed in 464 morbidly obese patients to ﬁll in
the TFEQ established by Stunkard and Messick (1985). Mean score
values 6 SD for each genotype are represented.
DOI: 10.1371/journal.pbio.0000068.g005
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analyses. As hyperinsulinemia is a characteristic of obese
patients, mean values of Ln GAD65Ab indexes were higher in
the 575 unrelated morbidly obese patients (3.81 6 0.35)
compared to the 376 nonobese normoglycemic subjects (3.71
6 0.36; p ¼ 0.007 for the Kolmogorov–Smirnov test), in
agreement with previous ﬁndings (Rolandsson et al. 1999;
Weets et al. 2001). In the control group, SNPs  243 A.G,
þ61450 C.A, and þ83897 T.A were associated with Ln
GAD65Ab adjusted for age and BMI (Figure 6). Homozygote
variant genotypes (GG, AA, AA for SNPs  243 A.G, þ61450
C.A, and þ83897 T.A) showed lower GAD65Ab levels (p
values for the Kruskal–Wallis test: 0.003, 0.047, and 0.006 for
SNPs 243 A.G,þ61450 C.A, andþ83897 T.A, respectively)
(Figure 6A). A similar nonsigniﬁcant trend for association
between GAD2 SNPs and GAD65Ab indexes was observed in
the morbidly obese group (Figure 6B). Thus, promoter GAD2
SNPs associated with obesity were associated with lower levels
of antibodies in normal weighted subjects, whereas the
elevated GAD65Ab levels of obesity-induced hyperinsuline-
mia in morbidly obese patients should mask this link.
As GABA release from b cells was suggested to strongly
inhibit insulin secretion (Shi et al. 2000), we looked in
nondiabetic control subjects for a potential effect of GAD2
SNPs on fasting insulin and on the b-cell function assessed
with the homeostasis model (HOMA-B%). We found that
subjects homozygous (AA) for þ83897 T.A showed lower
fasting insulin levels and HOMA -B indexes (p values for
Kruskal–Wallis test: 0.0091 and 0.01, respectively, for fasting
insulin and HOMA-B) (Figure 7), suggesting a deleterious
effect of GAD2 SNPs on insulin secretion, probably through
an increase of the GABA pool in pancreatic b cells mediated
by GAD65 higher enzymatic activity.
Discussion
All together, the identiﬁcation of a protective effect of the
wild-type alleles at SNPs 243 A.G,þ61450 C.A, andþ83897
T.A supports the hypothesis that the GAD2 gene may
modulate the risk of morbid obesity in the French popula-
tion. Analyses of GAD2 SNP haplotypes allow us to conclude
that SNP 243 A.G and an haplotype including SNPsþ61450
C.A and þ83897 T.A displayed separate effects, as these
genetic risk factors have never been encountered on the same
haplotype.
These assumptions are primary based on case-control
studies in French Caucasian adult patients, a population still
protected against massive obesity, as its prevalence is three to
ﬁve times lower compared to the United States’ population.
As our initial affected sibpair linkage study only included
individuals with adult onset of obesity, few families have
parental genotype information. However, to exclude false-
positive association (due to population stratiﬁcation) and to
assess the contribution of GAD2 SNPs to the observed linkage
on Chromosome 10p12, we performed studies to examine
familial association and association with the evidence of
linkage in the nuclear families from the original population
showing linkage on this locus. We observed a modest but
signiﬁcant evidence of association with obesity and the
linkage signal. For SNP þ61450 C.A, at-risk homozygous-
bearing (A–A) affected sibpairs (17 nuclear families) displayed
a signiﬁcant LOD score of 4.13. Remaining affected sibpairs
nonconcordant for this genotype displayed alone a LOD
score of 1.75 at this locus. Although this suggests that a
unique SNP of the GAD2 gene could explain a signiﬁcant part
of the linkage on Chromosome 10p12 (p ¼ 0.02–0.06), the
effect of this SNP, in terms of relative risk, given the
Figure 6. Ln GAD65Ab Levels Adjusted for Age and BMI According to the
Genotypes at SNPs  243 A.G, þ61450 C.A, and þ83897 T.A
Mean level values 6 SD are displayed for each genotype. Wild-type
are AA, CC, TT; heterozygous are AG, CA, TA; and homozygous are
GG, AA, AA, respectively, for each SNP. (A) Nonobese normoglycemic
subjects. (B) Morbidly obese patients.
DOI: 10.1371/journal.pbio.0000068.g006
Figure 7. Fasting Insulin and HOMA
Fasting insulin (A) and assessment of HOMA-B% (B) in 376 nonobese
normoglycemic subjects according to the genotypes at SNPs  243
A.G, þ61450 C.A, and þ83897 T.A. Mean level values 6 SD are
displayed for each genotype. Wild-type are AA, CC, TT; heterozygous
are AG, CA, TA; and homozygous are GG, AA, AA, respectively, for
each SNP.
DOI: 10.1371/journal.pbio.0000068.g007
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frequency of 32% in the morbidly obese cohort, is not
compatible with such a high MLS. Therefore, it is very likely
other SNPs and/or genes located nearby on Chromosome 10p
could contribute to the observed linkage.
SNP  243 A.G, although shown to be associated with
morbid obesity in case-control cohorts and to modulate the
GAD2 promoter activity, did not show signiﬁcant evidence of
familial association with obesity and the linkage signal. To
observe a linkage, we need at least one of the risk factors to be
heterozygous for parents and transmitted to affected off-
spring. Indeed, the risk G allele at the  243 locus is less
frequent than its counterpart at theþ61450 locus (0.21 versus
0.32), and if 17 homozygous-bearing (A–A) affected sibpairs
were scored for the þ61450 SNP, only three homozygous-
bearing (G–G) affected sibpairs were scored for the 243 SNP.
Thus, an association with obesity and the linkage signal for
the  243 SNP, if it exists, may remain undetected. However,
the effect of the gene does not necessarily lie only on one
SNP. It is very possible that other variations in the gene, as
 243 A.G, may have an effect, although undetected by
linkage.
We believe that our case-control data showing association
between GAD2 SNPs and morbid obesity do not result from a
stratiﬁcation bias, as there is little allelic heterogeneity in
European populations (Ardlie et al. 2002b), and moreover our
family-based data support this association. It is noteworthy
that only 16% of the obese subjects included in case-control
analyses were part of the genome-scanned and ﬁne-mapped
families, ruling out that the observed association is speciﬁc to
this small group. In this respect, results remained qualita-
tively similar (but less signiﬁcant, as the number of subjects
was lower) when removing these obese probands from the
case-control studies (ORs of 1.28, 95% CI [1.04–1.59], p¼0.02;
1.17, 95% CI [0.97–1.41], p¼0.1; and 1.13, 95% CI [0.91–1.41],
p¼0.296, respectively, for SNPs 243 A.G,þ61450 C.A, and
þ83897 T.A).
SNPs þ61450 C.A and þ83897 T.A are located, respec-
tively, in GAD2 intron 11 and 15 and their functional role is
not obvious. On the other hand, the hypothesis of a
functional effect for SNP  243 A.G is further supported
by transcriptional activity studies, clearly showing that the G
allele of SNP  243 A.G increased GAD2 promoter activity
although two nearby promoter SNPs ( 1600 G.A and  2004
A.T) in strong LD with SNP  243 A.G did not modulate
promoter activity. As suggested by EMSA, a nuclear protein
that remains to be identiﬁed could have an higher afﬁnity for
the G allele. Furthermore, obese homozygous carriers of the
G allele at 243 A.G SNP were characterized with overeating
features as evaluated by the TFEQ. They had signiﬁcantly
higher indexes of hunger and disinhibition, which character-
ize higher sensitivity to the sensorial stimulation of food,
leading in certain circumstances to a decreased ability to
control their food intake over the time.
The disinhibition score has also been highly associated with
binge-eating features (Heartherth and Polivy 1992; Lawson et
al. 1995). Eating behavior was shown to be partially heritable
(Faith et al. 1997), and several susceptibility loci were
suggested from genome-wide scan studies (Steinle et al.
2002). In this regard, Branson et al. (2003) recently reported
that binge-eating was a major phenotypic abnormality
associated with mutations in the melanocortin 4 receptor
(MC4-R), suggesting that MC4-R contributes to modulate
eating behavior. A signiﬁcant linkage on Chromosome 10p
was recently identiﬁed in bulimia nervosa, a psychiatric
disorder characterized by overeating and self-induced vomit-
ing (Bulik et al. 2003). Here, the probability to detect genetic
mutations massively increasing BMI is higher. Both our in
vitro and genetic ﬁndings suggest that GAD2 SNPs may have
contributed to the worsening of obesity in this population,
possibly though a disability of the rare allele carriers in
controlling their food intake. Further clinical investigation in
bearers would be needed to validate this hypothesis. At
present, we speculate that an increased activity of the GAD2
gene may increase the GABA pool in the hypothalamus, thus
enhancing GABA orexigenic effects, resulting in an altered
feeding behavior. Several lines of investigation support a role
for GABA in regulation of feeding behavior. Investigation in
turkeys has demonstrated that intracerebroventricularly
injection of varying doses of muscimol, a potent GABA
agonist, caused a dose-dependant increase of food intake
(Denbow 1991). Transgenic mice ubiquitously overexpressing
the GABA transporter exhibited heritable obesity, with
increased body weight and fat deposition (Ma et al. 2000).
GABA is coexpressed in the subpopulation of NPY neurons in
the arcuate nucleus, suggesting that GABA and NPY interact
in the paraventricular nucleus to stimulate food intake
(Ovesjo et al. 2001). Indeed, the gut-secreted hormone
PYY3–36, which potently inhibits food intake in both rodents
and in human, acts by inhibiting NPY neurons, thus
disinhibiting pro-opiomelanocortinergic (POMC) neurons
through a GABA-mediated process (Batterham et al. 2002).
The dopaminergic neurons were previously suggested to be
involved in behavioral disorders, such as eating disorders.
The low brain dopamine activity found in obese subjects
could predispose them to excessive use of food (Wang et al.
2001). Dopamine D2 receptor polymorphisms were reported
to be associated with obesity in Pima Indians from Arizona
(Jenkinson et al. 2000). The dopaminergic signal promotes the
functional differentiation of GABAergic neurons by regu-
lation of expression of GAD65 and GAD67, suggesting
interactions between dopamine and GABA pathways in the
regulation of food intake (Laprade and Soghomonian 1999).
In addition to the central effects of GAD2, a peripheral
contribution might also be suggested. The GAD2 gene is
highly expressed in pancreatic b cells and GAD65 is the most
important autoantigen in type 1 diabetes. In each b cell, there
are 3,000 small GABA-containing neuron-like secretory
vesicles, similar to the clear synaptic vesicles in nerve
terminals. It has been speculated that GABA-containing
microvesicles are released by Ca
2þ-dependent exocytosis
and may have an autocrine/paracrine function within the
islet (Gu et al. 1993). GABA released from the b cell
accordingly inhibits insulin exocytosis by activation of
GABA-B receptors (G protein-coupled receptors) and in the
a cell suppresses glucagon release by activation of GABA-A
receptor Cl channels (Rorsman et al. 1989; P. Rorsman,
personal communication). Given the anorectic role of insulin
and of glucagon-related peptides in the CNS, it is also
possible that GAD2 SNP-related increase of the GABA pool in
pancreatic islets contributes to modulate food intake
(Niswender et al. 2003).
In order to be able to test this hypothesis in humans, we
analyzed the GAD65Ab level as a marker of b-cell activity and
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nondiabetic general population from Sweden, the ORs for
subjects in the highest BMI group to exceed the 95th or 99th
GAD65Ab percentile were 3.6 and 17.6, respectively (Ro-
landsson et al. 1999). Previously conﬁrmed among ﬁrst-degree
relatives of type 1 diabetes patients (Weets et al. 2001), this
correlation between obesity and GAD65Ab levels was also
observed in our French population and may be due to the
overstimulation of the b cells associated with obesity. In order
to have an indirect conﬁrmation of the GAD2 SNP functional
role, we then examined possible associations between the
SNPs  243 A.G, þ61450 C.A, and þ83897 T.Aa n d
GAD65Ab and plasma insulin levels. These analyses showed
lower GAD65Ab levels (especially in the control group) and
lower insulin secretion indexes in homozygous variant
carriers at any of these SNPs. This is in agreement with a
negative regulation by GABA (generated by GAD65 in the b
cells) of the ﬁrst phase of insulin secretion in response to
glucose (Shi et al. 2000). The fact that GAD65Ab and related
insulin values are lower in GAD2 carriers of SNP variant
alleles but are higher in obese compared to normal-weighted
subjects may look like a paradox if one wants to see a direct
role of GAD65Ab in the development of obesity. Further, we
think that the presence of GAD65Ab is only a marker of
hyperinsulinemia and has nothing to do with the molecular
mechanisms responsible for obesity. Instead, GAD65Ab levels
should be considered as an intermediary phenotype for GAD2
gene higher expression in subjects carrying the at-risk SNPs
that in turn may impair insulin secretion, decrease GAD65Ab
secretion, and ultimately inﬂuence food intake behavior
through insulin central effects.
In conclusion, our data point out GAD2 gene as a candidate
for morbid obesity. Previous studies in cases with extreme
forms of obesity have shown mutations in genes involved in
the leptin–melanocortin pathway (Clement et al. 2002), which
primarily impair food intake regulation. If conﬁrmed, our
results are novel evidence for a role of GABA, which interacts
in the NPY and POMC neurons’ cross-talk, but also may
modulate the anorectic insulin release by the b cells (Schwartz
et al. 2003) in the polygenic predisposition to the severe
obesity in human.
Materials and Methods
Study Populations
Fine mapping was performed using a set of 188 nuclear families
collected through the Department of Nutrition of the Ho ˆtel Dieu
Hospital in Paris (46%) or by a multimedia campaign at the Institut
Pasteur de Lille (54%) in France. Families were ascertained through a
proband with a BMI of greater than 40 kg/m
2 and at least one
additional sibling with a BMI of greater than 27 kg/m
2.
Association studies of the GAD2 gene were performed using a ﬁrst
set of 349 unrelated morbidly obese patients (mean BMI, 47.3 6 7.4
kg/m
2; mean age, 46 6 12 y; women/men, 280/69). SNPs showing a
signiﬁcant association (or even a trend toward association) were
genotyped in an additional group of 226 unrelated morbidly obese
subjects (mean BMI, 47.45 6 7.69 kg/m
2; mean age, 47.3 6 11.7 y;
women/men, 165/61) and in a set of 383 unrelated moderately obese
subjects (mean BMI, 34.3 6 4.13 kg/m
2; mean age, 51.2 6 14.8 y;
women/men, 201/182), randomly selected from a collection of French
patients. Of the morbidly obese, 16% (91/575) were included in the
original linkage cohort (Hager et al. 1998).We used as control groups
a ﬁrst set of 376 unrelated nonobese and normoglycemic husbands
and wives from type 2 diabetes families (Vionnet et al. 2000) (mean
BMI, 22.8 6 2.44 kg/m
2; mean age, 58.3 6 14.1 y; women/men, 227/
149) and a second set of 270 unrelated nonobese and normoglycemic
subjects selected from 294 families from a general population
recruited on a geographical basis in two towns from Northern
France (the so-called Fleurbaix–Laventie study) (mean BMI, 23.3 6
2.2 kg/m
2; mean age, 44.3 6 3.85 y; women/men, 153/117).
In our population, to assess parameters of food-eating behavior,
the subjects ﬁlled in the TFEQ established by Stunkard and Messick
(1985), which evaluates the cognitive restraint of eating, disinhibition,
and hunger. Scores for the TFEQ were available for 464 morbidly
obese patients with familial history of obesity and the range of scores
for hunger was 1–14; for disinhibition, 1–18; and for restraint, 1–21.
Fasting insulin was measured with standard protocols, and b-cell
function (% B) was assessed with HOMA (Matthews et al. 1985).
GAD65Ab Assays
Plasma samples were analyzed for GAD65Ab in radioligand
binding assays (Grubin et al. 1994). [
35S]Methionine-labeled GAD65
was produced by in vitro coupled transcription/translation with SP6
RNA polymerase and nuclease-treated rabbit reticulocyte lysate
(Promega, Madison, Wisconsin, United States) as previously described
(Grubin et al. 1994). The in vitro translated proteins were kept at
 808C and used within 2 wk of preparation. The upper level of
normal was established by analyzing sera obtained from nondiabetic
subjects. The interassay %CV for the positive control sample (WHO
standard 97/550 6) was 15% for GAD65Ab. In the third International
Combined Autoantibody Workshop (Verge et al. 1998), our assay
showed 70% sensitivity and 98% speciﬁcity for GAD65Ab.
Fine Mapping
In 188 nuclear families comprising 620 individuals, we genotyped
16 polymorphic markers from D10S548 to D10S220 with a density of
one marker every centimorgan. Two-point and multipoint analyses
were performed using the GeneHunterPlus software (Kruglyak and
Lander 1995). The statistics were the MLS (Risch 1990).
Screening the GAD2 Gene
The 16 exons and UTRs (upstream 59 UTR and downstream 39
UTR) were screened in 24 unrelated obese patients (mean BMI, 37.9
6 5.92 kg/m
2; mean age, 48.7 6 8.5 y; women/men, 16/8) randomly
selected among families contributing to the linkage at the Chromo-
some 10p locus and in 24 unrelated nonobese normoglycemic control
subjects (mean BMI, 22.57 6 1.97 kg/m
2; mean age, 61.8 6 10 y;
women/men, 16/8) selected from French pedigrees.
DNA sequencing was performed using an automated ABI Prism
3700 DNA sequencer in combination with the Big Dye Terminator
Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster
City, California, United States). The obtained sequences were
compared with the published sequence for the human GAD2 gene.
Sequences of primers used for PCR-direct sequencing are available
from the authors.
Genotyping
Fifteen SNPs of the GAD2 gene were genotyped by direct
sequencing and/or with the LightCyclere (Roche Diagnostics, Basel,
Switzerland) assay based on hybridization probes labeled with
ﬂuorescent dyes that allow ﬂuorescence resonance energy transfer
(Blomeke et al. 1999). Sequences of primers pairs, labeled with
ﬂuorescein and LC Red 640 (Roche Diagnostics), are available from
the authors.
Statistical Analyses
Case-control studies. Comparison of allelic frequencies between
cases and controls was achieved through the v
2 test and the p value was
empirically computed with the program CLUMP (Sham and Curtis
1995). This method is of special interest when applied to polymorphic
markers (D10S197) because of the large number of alleles.
All SNPs were complied with Hardy–Weinberg proportions; then,
we presented the OR and the 95%CI for allelic effect. Scores for the
TFEQ, GAD65Ab index, fasting insulin, and b-cell function (%B) were
compared within 376 unrelated nonobese and normoglycemic and
464 morbidly obese subjects, using the nonparametric Wilcoxon–
Kruskal–Wallis test. Haplotype frequencies were determined and
were compared between groups with the PMþEHþ (Zhao et al. 2000)
and the HTR (Zaykin et al. 2002) softwares. HTR also allows rapid and
robust comparison of haplotype frequencies between two groups as
well as association testing between haplotypes and quantitative traits.
The method is equivalent to multiple regression, where covariates
are the probability of presence of each haplotype. We then get
signiﬁcance tests for the whole effect of haplotypes (Apval) on the
trait and individual tests for each haplotype (Hpval). The HTR
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can thus correct for multiple SNPs testing. The expectation
maximization (EM) algorithm is used to infer individual haplotype
probability distribution. We assigned the two most likely haplotypes
to each subject, either affected or unaffected. The population
probabilities for each haplotype were estimated in the whole group,
affected and unaffected, pooled together. PMþEHþ estimated the
haplotype frequencies and their log-likelihood in each group
separately (Laff and Lunaff) and in the whole sample (Lall) through
an EM algorithm, and a likelihood ratio test (Lall (LaffþLunaff))
evaluated heterogeneity in haplotype frequencies between the
groups. The main difference between these two methods lies in the
group where frequencies are estimated. Haplotypes were recon-
structed from population genotype data, using SNPHAP (Stephens et
al. 2001) software.
Familial association. We used three methods that allowed us to
extract as much information as possible from our data, which are not
well tailored for family-based tests.
Pedigree Disequilibrium Test (PDT). The Pedigree Disequilibrium Test
(Martin et al. 2000) allows us to evaluate evidence of LD in general
pedigree data. This method considers all the possible informative
triads and discordant sibpairs (DSPs) in the pedigree. A variable is
created that is either the differ e n c eb e t w e e nt h en u m b e ro f
transmissions and the nontransmission for a given allele in a triad
or the difference between the frequency of this allele in affected and
unaffected member of the DSP. The sum of this value is weighted by
the number of units (triad and DSP) in each pedigree. The new
random variable D is then summed over all the pedigrees. It is
expected to be equal to 0 under the null hypothesis of no linkage and
no association and D/=Var(D) follows a Normal with a mean of 0 and
a variance of 1.
We decided to use the option that computes the statistic for the
trios and only when the founders are untyped uses DSP. This seems to
be a sound approach when we are not sure of the status of the
unaffected individuals and want to give them minimum weight.
Family-Based Association Test (FBAT). The FBAT (Lake et al. 2000)
method deﬁnes a statistical test that reﬂects association between a
phenotype (T) and a marker value (X). The tests uses the generic form
S ¼ T X as a test statistic, where summation is over all offspring in
all families in the dataset. The distribution of S under H0 is calculated
using the distribution of offspring genotype, conditional on the trait
T and on the parental genotype, or the sufﬁcient statistics when
parental genotype is unobserved. The value S   E(S)/=Var(S) follows
a Normal (0,1). As we are in a region of linkage, with several
individuals in each family, we chose the option  e that calculates an
empirical variance and provides a valid test of association in this case.
The phenotype was coded 1 for affected and 0 for unaffected, giving
them a null weight in the ﬁnal statistic. This is an affected-only test,
although the genotypes of unaffected are used when the parents’
genotypes are missing.
The FBAT program allows for haplotype tests. We therefore
repeated this association test on haplotypes.
Association with Evidence of Linkage. We sought to test whether any of
the SNPs was responsible for the observed linkage. We therefore split
the sample of affected sibpairs onto pairs concordant for genotype
categories (1 1, 1 2, 2 2, 1 X, 2 X). Note that the sets of 1 X and 2 X,
where X represents allele 1 or 2, are overlapping. If a genotype is
responsible for the observed linkage, we expect that the MLS of the set
of the pairs concordant, or identical by state (IBS) for this genotype,
whichwe callMLSg,is signiﬁcantlyhigherthan whatisexpected under
H0. Inourcase,H0 includeslinkageand association. Wethenderiveap
value through simulation after preserving the linkage information
(i.e., the identical by descent [IBD] status for each pair) and the
association (the number of pairs concordant for the genotype).
It is worth pointing out that genotype category-speciﬁc MLSg
cannot be considered as a traditional MLS. Indeed, we select pairs
where IBS is 2 and the IBD status is not independent of the IBS status.
Therefore, the MLSg does not follow a mixture of v
2 tests with 1 or 2
df, as usual. The p value is obtained through simulation under H0.
We simulate the parents’ genotype and drop the alleles in the
offspring according to the transmission probabilities (½–½) and the
IBD status. For each pair, its IBD status is drawn from the zij
distribution, where j¼(0,1,2) is the number of alleles IBD and j is the
pair’s index. These values were obtained with the GeneHunterPlus
software. Note that in parents, we just determine the number of 1 and
2 alleles, from an original allelic frequency ( f1), and then just shufﬂe
the alleles among them. Therefore, we will have the same allelic
frequency in founders for each replicate. For a valid test of
association with evidence of linkage, we count the number of times
the replicate LOD score exceeds the observed LOD score, for a
number of pairs equal to the original (if there are N pairs 11 11, we
will use only the replicates where we observe N pairs simulated). This
method was used by Horikawa et al. (2000) and Sun et al. (2002).
Plasmid Construction, Cell Line, and Luciferase Assay
Sense (cgggtctctgctttgttagc) and antisense (tttggagactggagcaggtc)
oligonucleotides were used to amplify a 2,200 bp fragment of the
GAD2 promoter from four homozygous individuals (wild-type,  243
G/G,  1600 A/A, and  2000 T/T). PCR fragments were inserted into
the pGL3-basic vector (Promega) using the BglII and HindIII
restriction sites present in the vector and the sense and the antisense
oligonucleotides, respectively. Preparations of plasmids representing
the genotypes  2000/ 1600/ 243 (A/G/A, G/G/A, A/A/A, and A/G/T)
were performed, and the genotypes of the constructs were conﬁrmed
by sequencing.
Murine insulinoma cells bTC3 were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) (Life Technologies, Carlsbad, California,
United States) supplemented with 10% fetal calf serum, penicillin (10
U/ml), streptomycin (100 mg/ml), and L-glutamin (2 mM) and
incubated at 378C, under an atmosphere of 5% CO2. Cells were
transiently transfected with 1 lg of each construct and with 50 ng of
pRLTK plasmid expressing Renilla luciferase for 48 h using Trans-
Fast
TM (Promega) according to the manufacturer’s instructions. Cells
were lysed and the ﬁreﬂy and the Renilla luciferase activities were
measured usingthe dual-luciferaseassay system (Promega). The pGL3-
basic vector was used as negative control and the pGL3-SV40 vector as
positive control. Each transfection was performed in duplicate and
replicated ﬁve times. The normalized relative luciferase units (RLUs)
for each construct correspond to the ﬁreﬂy/Renilla RLU ratio.
EMSA
Nuclear extracts were prepared from murine insulinoma cells
bTC3, which were grown in DMEM high-glucose media supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, and 2-mercapto-
ethanol and incubated at 378C under an atmosphere of 5% CO2.
Nuclear extracts were prepared as previously described (Schreiber et
al. 1989). Double-stranded DNA probes containing the  243 A.G
polymorphism were labeled with T4 polynucleotide kinase using
[c-
32P]ATP and then puriﬁed using a mini-Quick Spin Columns
system (Roche Applied Science, Basel, Switzerland). Binding reactions
were performed in a total volume of 20 ll, with 5 lg of nuclear
extract in a buffer containing 40 mM HEPES, 400 mM NaCl, 0.4 mM
EDTA, 0.1 lg/ll dI–dC, 40% glycerol, 4 mg/ml bovine serum albumin,
and 2 mM DTT. After a 15 min incubation at room temperature,
probes (10,000 cpm) were added. The protein–DNA complexes were
resolved on a 4% polyacrylamide:bisacrylamide (29:1) gel. Gels were
dried under vacuum and exposed to X-ray ﬁlms (Kodak, Rochester,
New York, United States). Quantiﬁcation of the signal was performed
with NIH Image software (http://rsb.info.nih.gov/nih-image/).
Supporting Information
Accession Numbers
Accession numbers for the genes discussed in this paper are
dopamine D2 receptor (LocusLink ID 1813), GAD2 (LocusLink ID
2572 and Genbank g182931), melanocortin 4 receptor (LocusLink ID
4160), MYO3A (LocusLink ID 53904), and neuropeptide Y (LocusLink
ID 4852).
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